[go: up one dir, main page]

EA201391700A1 - АГОНИСТЫ РЕЦЕПТОРА mGlu2 - Google Patents

АГОНИСТЫ РЕЦЕПТОРА mGlu2

Info

Publication number
EA201391700A1
EA201391700A1 EA201391700A EA201391700A EA201391700A1 EA 201391700 A1 EA201391700 A1 EA 201391700A1 EA 201391700 A EA201391700 A EA 201391700A EA 201391700 A EA201391700 A EA 201391700A EA 201391700 A1 EA201391700 A1 EA 201391700A1
Authority
EA
Eurasian Patent Office
Prior art keywords
agonis
mglu2
receptor
schizophrenia
treatment
Prior art date
Application number
EA201391700A
Other languages
English (en)
Other versions
EA023553B1 (ru
Inventor
Тереза Тсе Кл Ман
Джеймс Аллен Монн
Карлос Монтеро Салгадо
Лурдес Прието
Лесли Вальтон
Дэвид Эдвард Таппер
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201391700A1 publication Critical patent/EA201391700A1/ru
Publication of EA023553B1 publication Critical patent/EA023553B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В настоящем изобретении предложены новые агонисты mGlu2, подходящие для применения для лечения биполярного расстройства, шизофрении и генерализованного тревожного расстройства.
EA201391700A 2011-06-17 2012-06-07 Агонисты рецептора mglu2 EA023553B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11382208 2011-06-17
US201161522791P 2011-08-12 2011-08-12
PCT/US2012/041229 WO2012173850A1 (en) 2011-06-17 2012-06-07 Bicyclo (3.1.0) hexane- 2, 6 -dicarboxylic acid derivatives as mglu2 receptor agonist

Publications (2)

Publication Number Publication Date
EA201391700A1 true EA201391700A1 (ru) 2014-04-30
EA023553B1 EA023553B1 (ru) 2016-06-30

Family

ID=47357416

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391700A EA023553B1 (ru) 2011-06-17 2012-06-07 Агонисты рецептора mglu2

Country Status (20)

Country Link
US (1) US9296710B2 (ru)
EP (1) EP2721012B1 (ru)
JP (1) JP5945592B2 (ru)
KR (1) KR101598679B1 (ru)
CN (1) CN103596933B (ru)
AU (1) AU2012271024B2 (ru)
BR (1) BR112013031928B1 (ru)
CA (1) CA2836485C (ru)
CY (1) CY1117682T1 (ru)
DK (1) DK2721012T3 (ru)
EA (1) EA023553B1 (ru)
ES (1) ES2587204T3 (ru)
HR (1) HRP20160676T1 (ru)
HU (1) HUE030171T2 (ru)
MX (1) MX2013014802A (ru)
PL (1) PL2721012T3 (ru)
PT (1) PT2721012T (ru)
RS (1) RS54888B1 (ru)
SI (1) SI2721012T1 (ru)
WO (1) WO2012173850A1 (ru)

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993006127A1 (en) 1991-09-17 1993-04-01 Warner-Lambert Company Novel amino acid prodrug renin inhibitors
US5576323A (en) 1993-12-03 1996-11-19 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5849525A (en) 1994-03-09 1998-12-15 Brigham And Women's Hospital, Inc. Compositions corresponding to a proton-coupled peptide transporter and methods of making and using same
BR9611511A (pt) 1995-11-16 1999-05-04 Lilly Co Eli Derivados de aminoácidos excitatórios
GB9605429D0 (en) * 1995-11-16 1996-05-15 Lilly Co Eli Excitatory amino acid receptor antagonists
US5688826A (en) 1995-11-16 1997-11-18 Eli Lilly And Company Excitatory amino acid derivatives
US5952294A (en) 1996-07-31 1999-09-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptidyl prodrugs and methods of making and using the same
ZA983930B (en) 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
ES2191412T3 (es) 1998-01-28 2003-09-01 Taisho Pharmaceutical Co Ltd Derivados de aminoacidos que contienen fluor.
PT1110943E (pt) 1998-08-31 2004-08-31 Taisho Pharmaceutical Co Ltd Derivados 6-fluorobiciclo¬3.1.0|hexano
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
WO2002000605A1 (fr) 2000-06-28 2002-01-03 Taisho Pharmaceutical Co., Ltd. Nouveaux derives d'acide dicarboxylique
WO2002055485A1 (en) 2001-01-11 2002-07-18 Eli Lilly And Company Prodrugs of excitatory amino acids
CN1267407C (zh) 2001-01-11 2006-08-02 伊莱利利公司 兴奋性氨基酸前体药物
WO2002068380A1 (en) * 2001-02-22 2002-09-06 Eli Lilly And Company Synthetic excitatory amino acids
JP2005505506A (ja) 2001-06-12 2005-02-24 イーラン ファーマスーティカルズ、インコーポレイテッド アルツハイマー病の治療に有用な大環状分子
DK1459765T3 (da) 2001-12-27 2008-10-06 Taisho Pharmaceutical Co Ltd 6-fluorbicyclo 3.1.0 hexan-derivater
CA2478227A1 (en) 2002-04-03 2003-10-16 Eli Lilly And Company Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist
US20050192273A1 (en) 2002-04-03 2005-09-01 Johnson Bryan G. Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist
MXPA04012518A (es) 2002-06-11 2005-02-17 Lilly Co Eli Profarmacos de aminoacidos excitadores.
CN100482680C (zh) * 2002-06-11 2009-04-29 伊莱利利公司 兴奋性氨基酸前药
ES2355144T3 (es) * 2003-06-26 2011-03-23 Taisho Pharmaceutical Co., Ltd. Derivado de éster 2-aminobiciclo 3.1.0 hexano-2,6-dicarboxílico.
WO2005000790A1 (ja) * 2003-06-26 2005-01-06 Taisho Pharmaceutical Co., Ltd. ２－アミノビシクロ[３．１．０]ヘキサン－２，６－ジカルボン酸誘導体
RS55469B1 (sr) * 2009-11-18 2017-04-28 Suven Life Sciences Ltd Biciklična jedinjenja kao ligandi alfa4beta2 nikotinskih acetilholinskih receptora
JO2978B1 (en) * 2009-12-21 2016-03-15 ايلي ليلي اند كومباني MGLU2 aids

Also Published As

Publication number Publication date
DK2721012T3 (en) 2016-08-15
KR101598679B1 (ko) 2016-02-29
PT2721012T (pt) 2016-07-27
MX2013014802A (es) 2014-01-24
EA023553B1 (ru) 2016-06-30
WO2012173850A1 (en) 2012-12-20
BR112013031928B1 (pt) 2022-05-24
KR20140009568A (ko) 2014-01-22
CN103596933B (zh) 2016-03-23
RS54888B1 (sr) 2016-10-31
CA2836485C (en) 2016-12-13
JP2014517035A (ja) 2014-07-17
HUE030171T2 (en) 2017-05-29
SI2721012T1 (sl) 2016-08-31
PL2721012T3 (pl) 2017-05-31
ES2587204T3 (es) 2016-10-21
EP2721012A1 (en) 2014-04-23
CY1117682T1 (el) 2017-05-17
US9296710B2 (en) 2016-03-29
AU2012271024B2 (en) 2015-07-09
BR112013031928A2 (pt) 2016-12-13
JP5945592B2 (ja) 2016-07-05
CN103596933A (zh) 2014-02-19
AU2012271024A1 (en) 2013-11-21
CA2836485A1 (en) 2012-12-20
US20140113944A1 (en) 2014-04-24
EP2721012B1 (en) 2016-05-25
HRP20160676T1 (hr) 2016-07-15

Similar Documents

Publication Publication Date Title
MX2019014654A (es) Agonistas de fgfr1 y sus metodos de uso.
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
MX2021000007A (es) Formulaciones de enzalutamida.
UY34352A (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
UY34472A (es) Derivados modificados de 4-fenil-piridina
EA201201357A1 (ru) Антитела к cd40
EA201491617A1 (ru) Соединения для лечения спинальной мышечной атрофии
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
EA201400178A1 (ru) Лечение рака молочной железы
EA201490559A1 (ru) Композиция для лечения свища
EA201490778A1 (ru) АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ
EA201491303A1 (ru) Конденсированные тетра- или пентациклические дигидродиазепинокарбазолоны в качестве ингибиторов parps
ECSP12011989A (es) Agonistas de mglu2
EA201491610A1 (ru) Модуляторы x рецепторов печени
ECSP14002542A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
EA201691831A1 (ru) Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
UY34543A (es) Derivados de sulfonilaminopirrolidinona, su preparación y aplicación terapéutica.
CO7160067A2 (es) Formulaciones de agonistas del receptor de somatostatina
EA201691788A1 (ru) Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов
EA201270315A1 (ru) Новые формы полициклического соединения
EA201590615A1 (ru) Стимулирующие лактацию композиции на основе фосфатидилсерина
EA201491522A1 (ru) Способы лечения нарушения походки и/или равновесия у пациентов с рассеянным склерозом с использованием аминопиридина
EA201391700A1 (ru) АГОНИСТЫ РЕЦЕПТОРА mGlu2
UY34535A (es) Nuevo uso terapéutico de antagonistas del receptor p75.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM